Alkermes Eyes Global Phase 3 Trial After Encouraging Data From Sleep Disorder Study
1. Alkermes' alixorexton shows positive results in phase 2 narcolepsy study. 2. Statistically significant improvements observed in excessive daytime sleepiness. 3. Alixorexton generally well tolerated; no serious adverse events reported. 4. Phase 3 trial expected to start in early 2026. 5. ALKS stock drops 8.03%, closing at $31.1.